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Caveolin-1 and -2 (CAV1, CAV2) are closely linked genes localised to the fragile region of 7q31 (FRA7G), and loss of heterozygosity
involving this region has been reported in breast cancer. Several studies have suggested that CAV1 is a negative regulator of HER2/
neu signal transduction in vitro. However, the clinical significance of CAV1 in breast cancer has not yet been clarified. We examined
quantitatively the mRNA levels of CAV1, CAV2 and HER2/neu in 162 cases of breast cancer using real-time PCR. Caveolin-1 and -2
protein expression was also examined by Western blotting and immunohistochemistry. We then evaluated for correlations between
CAV1, CAV2 and HER2/neu gene expression and clinicopathologic factors in the 162 breast cancer cases. Results showed higher
HER2/neu mRMA levels and lower CAV1 and CAV2 mRMA levels in breast cancer tissues than in corresponding normal tissues
(Po0.001). Caveolin-1 and -2 protein expression levels were also suppressed in cancer tissues compared to normal tissues by
Western blotting. Immunohistochemistry revealed that CAV1 and CAV2 proteins were abundantly expressed in mammary gland
myoepithelial cells, but only weakly in ductalepithelial cells. Reduced CAV1 mRNA level was significantly associated with increasing
tumour size (P¼0.041), and negative oestrogen receptor status (P¼0.021). There was also a significant association between low
CAV2 mRNA level and negative progesterone receptor status (P¼0.013), and between high HER2/neu mRNA level and negative
hormonal receptor status (ER, P¼0.029, PgR, P¼0.019). While there was no relationship between HER2/neu and CAV1 mRNA
levels, a significant association between CAV1 and CAV2 mRNA levels was observed (Po0.001). Our results indicated that CAV1
suppression correlated closely with that of CAV2 in breast cancer, that CAV1 level was inversely correlated with tumour size, and
that CAV1 and CAV2 levels were correlated with hormonal receptor status. Therefore, CAV1 and CAV2 play an important role in
tumour progression in breast cancer patients.
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Caveolae mediate molecular transport, cell adhesion and signal
transduction activities in the cell (Couet et al, 1997; Zhang et al,
2000; Razani et al, 2001). Caveolin-1 (CAV1), the major coat
protein of caveolae, has been reported to interact with various
intracellular signalling molecules including growth factors such as
epidermal growth factor receptor (EGFR) (Couet et al, 1997;
Engelman et al, 1998; Kim et al, 2000) and oestrogen receptor (ER)
(Razandi et al, 2002; Zschocke et al, 2002). Some studies have
suggested that caveolin may function as a negative regulators of
signal transduction to HER2/neu, member of the EGF family. In
recent years, trastuzumab (Herceptin
s) has been used as the first-
line agent in the treatment of recurrent breast cancers that
overexpress HER2/neu. Interestingly, some breast cancer patients
with HER2/neu-overexpressing tumours do not respond well to
trastzumab treatment.
Several lines of evidence have suggested that caveolin expression
in malignancies may be clinically significant. For example, CAV1
expression is increased in prostate cancer (Yang et al, 1999),
oesophageal cancer (Kato et al, 2002) and ovarian cancer
(Davidson et al, 2001), but reduced in colon cancer (Bender et al,
2000), lung cancer (Ho et al, 2002) and sarcoma (Wiechen et al,
2001).
In the present study, we investigated the mRNA levels of CAV1,
Caveolin-2 (CAV2) and HER2/neu in breast cancer tissues from
162 cases by the real-time PCR to evaluate the clinical significance
of these genes.
MATERIALS AND METHODS
Surgical specimens
A totalof 162 female cases of breast cancer were available for study
and included 93 cases with both tumour and corresponding
normal specimens, and 69 cases with only tumour specimens.
Surgery was performed from October 1993 to October 1999 at the
Medical Institute of Bioregulation, Kyushu University Beppu, and
Oita Prefectural Hospital, Oita, Japan. Experimental protocols were
authorised by a Bioethics Committee and informed consent was
obtained from all patients in the study. The mean patient age was
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y55 years (range, 27–84 years), and median postoperative follow-up
was 41 months (range, 1–96 months). Hormonal status was
identified in 125 cases. All tumours are histopathologically
diagnosed as breast cancer. To avoid degeneration, cancer tissue
centres and corresponding cancer-free tissues were snap frozen in
liquid nitrogen immediately after excision, handled carefully to
avoid contamination with RNase, and stored at  801C until use.
mRNA quality was assessed in several representative cases using a
Bioanalyzer (Agilent Technologies, Japan) to exclude unsuitable
samples. Results showed samples were appropriate for further
study.
Cell culture
Human breast cancer cell lines, MCF-7, YMB-1, SKBR-3, MRKnu-1
and CRL-1500 were obtained from the Cell Resource Center at the
Biochemical Research Institute of Development, Aging and Cancer
(Tohoku University, Sendai, Japan). YMB-1 was maintained in
DMEM and MCF-7, SKBR-3, MRKnu-1 and CRL-1500 were
maintained in RPMI 1640. All cells lines were supplemented with
10% FBS and incubated at 371C in a 5% humidified CO2
atmosphere.
Preparation of cDNA from tissue specimens
Total RNA was extracted using the acid guanidinium thiocyanate/
phenol/chloroform extraction (AGPC) method. All samples were
treated with DEPC in Eppendorf tubes (Eppendorf, Germany) and
handled with gloves to avoid RNase contamination. Total RNA
aliquots were reverse transcribed into cDNA using oligo-dT
primers.
Quantitative analysis of mRNA of CAV1, 2 and HER2/neu
Reverse transcriptase reactions were performed as previously
described (Mori et al, 1993). Real-time PCR was performed using
the iCycler iQ detection system (Bio-Rad, Tokyo, Japan) and iQ
SYBR Green Supermix. Reactions were performed in 96-well plates
with Optical-Quality 8-tube Strips (Bio-Rad). The primer se-
quences for HER2/neu, CAV1, 2 and glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) are detailed in Table 1. The reactions for
both of them were subjected to 40 cycles for 30s at 951C, 1min at
601C, and 1 90s at 721C. Increases in fluorescence were measured
in real time during the extension step.
Fluorescence in situ hybridisation (FISH) of HER2/neu
Fluorescence in situ hybridisation on breast cancer cell lines was
performed at Ohtsuka Assay Inc., according to the PathVysion
(Vysis, Inc., Illinois, USA) protocol. Briefly, cultured breast cancer
cell lines on microscope slides were hydrated with Hemo-De
clearing agent (Vysis, Inc.) and a graded alcohols series. Slides
were air dried, pretreated (801C, 30min), and digested with
protease (371C, 10–20min) before hybridising with fluorescent-
labelled probes for the HER-2/neu gene and chromosome 17 alpha-
satellite DNA. Probes were premixed and predenatured in
hybridisation buffer for ease of use. Nuclei were counterstained
with intercalating fluorescent counterstain 40-60-diamidino-20-
phenylindole (DAPI). HER2 amplification ratio was calculated as:
HER2 total signal count/chromosome 17 total signal count.
Presence of HER2 amplification was defined as an HER2
amplification ratio of greater than 2.00.
Western blotting and immunohistochemistry for CAV1
and CAV2
For Western blot analysis, proteins were extracted from normal
and tumour tissues in five representative breast cancer cases.
Proteins were subjected to SDS–PAGE in 15% acrylamide gels
under reducing conditions and transferred to Immobilon-P
membranes (Millipore, Bedford, MA, USA). After blocking with
5% nonfat dry milk and 0.05% Tween-20 in PBS, blots were
incubated with CAV1 (BD Biosciences, CA, USA) and CAV2 (Santa
Cruz, CA, USA) mAb, used as culture supernatants diluted 1:2.
After several washings, blots were incubated for 1h with goat anti-
mouse IgG (1:5000) coupled to horseradish peroxidase, washed
extensively, and developed using a chemiluminescence Western
blotting kit (ECL, Amersham, Buckinghamshire, UK).
For immunohistochemistry, surgically resected specimens from
the same five cases of breast cancer tissues as used above and the
corresponding normal tissues were stored at  201C until use.
Frozen sections (4mm) were put onto silicon-coated glass slide and
stained with monoclonal antibodies, as above. Staining for CAV1
and CAV2 was performed on adjacent sections. Immunohisto-
chemical staining was performed as previously described (Mori
et al, 2000) using serum specific for human monoclonal CAV1 and
2 antibodies.
Statistical analysis
mRNA levels of CAV1, CAV2 and HER2/neu were calculated with
respect to GAPDH mRNA level. The 162 cases were diveided into
high and low mRNA groups (with 81 in each group), according to
mRNA level in each breast cancer (Figure 1), and correlation
between mRNA expression level and clinicopathologic factor were
analysed. The predictive value of mRNA expression level for
clinicopathological variables such as age, size of tumour, lymph
node metastasis, lymph vessel invasion, vascular vessel invasion,
oestrogen or progesterone receptor status were univariately tested
using a w
2 test. Correlation of each mRNA level was analysed using
the log rank test, and the cumulative survival rate was calculated
by the Kaplan–Meier method. All analyses were performed using
statistical software (Statview version 5.0; SAS Institute, Inc., Cary,
NC, USA), with a P-value of less than 0.05 considered statistically
significant.
RESULTS
Expression levels of CAV1, CAV2 and HER2/neu in normal
breast tissue, breast cancer tissue and cell lines
Low levels of CAV1 mRNA were detected in several breast cancer
cell lines (Figure 2), with CAV1 and CAV2 mRNA levels
significantly correlated with each other (r
2¼0. 927). The SKBR-3
cell line exhibited the highest HER2/neu mRNA level of the breast
cancer cell lines tested (SKBR-3, YMB-1, CRL-1500, MCF-7,
MRKnu-1), and FISH detected HER2/neu overexpression only in
SKBR-3 cells (Figure 3). Thus, HER2/neu mRNA levels were
concordant with HER2/neu FISH results. Comparison of breast
Table 1 Primers sets for the amplification of HER2/neu, CAVEOLIN 1,
CAVEOLIN 2 and glycelaldehyde-3-phosphate dehydrogenase
Gene Primer
HER2/neu Upper: 50 CCCCCAAAGCCAACAAAGAAA 30
Lower: 50GCCGCACATCCTCCAGGTAGC 30
Caveolin-1 (CAV1)
a Upper: 50 AAGGGACACACAGTTTTGACG 30
Lower: 50 TTGGCACCAGGAAAATTAAAA 30
Caveolin-2 (CAV2) Upper: 50 GGCGGACGTACAGCTCTTCAT 30
Lower: 50 GCCAGGAACACCGTCAGGAAC 30
GAPDH Upper: 50 GTCAACGGATTTGGTCTGTATT 30
Lower: 50 AGTCTTCTGGGTGGCAGTGAT 30
aIt is designed so that the arrangement of mutation of Caveolin-l (reported by Cancer
Research 61, 2361–2364, March 15, and 2001) might be included.
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cases showed higher HER2/neu mRNA levels and lower CAV1 and
CAV2 mRNA levels (Po0.001) (Figure 4).
We preliminary confirmed the concordant expression between
caveolins at the mRNA level by quantitative real-time PCR, and at
protein level by Western blot analysis in five representative breast
cancer samples (Figure 5). CAV1 and CAV2 protein levels were
downregulated in four representative breast cancer tissues
compared to corresponding normal breast tissues.
Immunohistochemical assays showed that the expression of
both caveolins was more abundant in the myoepithelial cells of the
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Figure 1 mRNA levels of CAV1, CAV2, and HER2 in breast cancer patients. We divided the 162 cases into 81 high and 81 low mRNA groups for each
mRNA examined. LOG (CAV1 mRNA/GAPDH mRNA) varies between  2.75 and 0.27 (mean,  1.23), LOG (CAV2 mRNA/GAPDH mRNA) varies
between  5.57 and 1.95 (mean,  1.13) and LOG (HER2 mRNA/GAPDH mRNA) varies between  2.18 and 6.43 (mean, 1.09).
−1
−2
−3
−4
−5
−6
−7
−8
−9
−10
−11
−4.5 −3.5 −2.5 −1.5 −1 −2 −3 −5 −4
L
O
G
 
C
A
V
1
/
G
A
P
D
H
LOG CAV2/GAPDH
r 2 = 0.927
MRKnu-1
YMB-1
CLR-1500
SKBR-3
MCF-7
SKBR-3 YMB-1 CRL-1500 MCF-7 MRKnu-1
CAV1/GAPDH 0.004 4.400E-6 4.590E-5 0.031 1.315E-10
CAV2/GAPDH 0.003 0.001 0.001 0.041 1.195E-5
Figure 2 Expression of CAV1 and CAV2 mRNA in breast cancer cell
lines. There was a statistical significant correlation between caveolin-1
(CAV1) and caveolin-2 (CAV2) expression in five breast cancer cell lines,
adjusted by linear regression analysis. Caveolin-1 and CAV2 expression
levels were adjusted according to GAPDH expression level. Letters A to E
in the graph and table indicate the actual data for the five breast cancer cell
lines.
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HER2 / GAPDH ratio
SKBR-3
YMB-1
CRL-1500
MCF-7
MRKnu-1
SKBR-3 YMB-1 CRL-1500 MCF-7 MRKnu-1
HER2/GAPDH 3.738 0.282 0.230 0.131 0.119
HER2 amplification ratio* 2.74 0.85 0.77 0.58 0.11
Figure 3 Expression of HER2/neu mRNA and HER2/neu amplification
ratio in breast cancer cell lines. *Fluorescence in situ hybridisation HER2
amplification ratio¼HER2 total signal count/Chr 17 total signal count
(HER2 amplification was defined as HER2 amplification ratio 42.00). There
was a statistically significant correlation between HER2/neu expression and
HER2/neu amplification (R¼0.968, R¼0.0068). The table shows actual
data of HER2/neu expression and HER2/neu amplification.
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while fewer expressions of CAV1 and CAV2 proteins were detected
in cancer tissues (data not shown).
Clinicopathologic significance of HER2/neu and CAV1, 2
As shown in Table 2, HER2/neu mRNA level showed an association
with hormonal receptor status (HER2/ER, P¼0.029:. HER2/PgR,
P¼0.019), and the high CAV1 mRNA level group tended to exhibit
small tumour size (P¼0.041) and positive ER status (P¼0.021).
Furthermore, there was a significant association between high
CAV2 mRNA level and positive progesterone receptor status
(P¼0.013). However, there were no significant differences in gene
expression with respect to disease-free survival (HER2, P¼0.745:
CAV1, P¼0.520: CAV2, P¼0.740). HER2/neu mRNA level was not
associated with that of CAV1 or CAV2 mRNA levels in breast
cancer samples (HER2/CAV1, P¼0.758: HER2/CAV2, P¼0.755)
(Table 3). In contrast, CAV1 mRNA level was significantly
associated with CAV2 mRNA level (Po0.001). There were no
significant associations with respect to histopathologic classifica-
tion in the 162 breast cancer cases.
DISCUSSION
CAV1 has been reported to interact with various intracellular
signalling pathways and is thought to suppress tumour growth in
breast cancer cell lines (Lee et al, 1998; Razani et al, 2001; Fiucci
et al, 2002). Prior studies have suggested that oncogenic
transformation results in reduced cellular levels of caveolin
(Glenney and Soppet, 1992; Sager et al, 1994; Koleske et al,
1995), and that this reduction probably contributes to a loss of
caveolae (Koleske et al, 1995). Lee et al (1998) found that the CAV1
levels were inversely correlated to breast cancer progression in
vitro and the overexpression of CAV1 resulted in substantial
growth inhibition of breast tumour cells, which normally had no
endogenous caveolin expression.
Our study confirmed that mRNA level of CAV1 and CAV2 were
significantly downregulated in human breast cancer tissues
compared to corresponding normal tissues (Po0.001), and that
CAV1 and CAV2 mRNA levels were significantly correlated with
each other in breast cancer cell lines and tissues. Hurlstone et al
reported that CAV1 was expressed in the normal breast tissue by
myoepithelial cells but not by ductal epithelial cells. This is in
agreement with our present study that observed much more CAV1
and CAV2 expression in myoepithelial cells than in ductal
epithelial cells in normal breast tissue by immunohistochemistry.
CAV1-null mice show a striking increase in the frequency and
size of multifocal dysplastic lesions in mammary grands, with the
nuclei and the nuclei of mammary grand cells showing anaplastic
characteristics with increased mitotic figures (Williams et al,
2003). This suggests that CAV1-mediated interactions between
myoepithelial cells and the rest of mammary gland may play an
important role in oncogenesis. In addition, our study found that
breast cancer patients with tumours that expressed low levels of
CAV1 mRNA tended to have larger tumour sizes, which supported
the hypothesis that CAV1 acts as a growth suppressor in breast
tumours (Lee et al, 1998).
There was a significant correlation between high CAV1 and
CAV2 mRNA level and positive hormonal receptor status. Razandi
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Figure 4 Comparison of CAV1, CAV2 and HER2/neu expression
between breast cancer tissue (T) and the corresponding normal mammary
gland (N). Average N/T ratio for CAV1, CAV2 and HER2/neu were
24.673.34, 37.974.42, and 1.1570.33, respectively. Significantly higher
CAV1 and CAV2 expression was observed in normal mammary glands,
while HER2/neu was abundant in tumour tissues. Caveolin-1
Caveolin-2
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Figure 5 Western blotting and immunohistochemistry of CAV1, 2. (A)
Protein expression of Caveolin-1 and Caveolin-2 in tumour and normal
tissues from five breast cancer cases by Western blotting. Expression was
measured using the free software program, NIH Image (version 1.62), and
the expression ratio of normal to tumour (N/T) was calculated to compare
with mRNA N/T ratios obtained by quantitative real-time RT–PCR. For
instance, the N/T ratio in case #4 was the lowest at the protein level and at
the mRNA level, while case #5 showed the highest N/T ratio for both
protein and mRNA. Also, the N/T ratios for Caveolin-1 and Caveolin-2 in
the representative five cases were concordant. (B) Localization of
Caveolin-1 and Caveolin-2 expression by immunohistochemistry. Caveo-
lin-1 (upper row) and Caveolin-2 (lower row) expression was abundant in
mammary gland myoepithelial cells of (right) and in the mammary duct
(left) in this representative normal breast tissue.
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proteins and activated a CAV1 promoter/luciferase reporter
construct transfected into in smooth muscle cells. CAV1 also
stimulated ER translocation to the cell membrane in MCF-7 cells,
inhibiting E2-induced ERK (MAPK) activation, required for DNA
synthesis and cell survival (Razandi et al, 2002). Thus, our results
support the hypothesis that CAV1 and CAV2 play an important
role in the process of hormonal translocation.
Our present results also suggested that HER2/neu level and
hormonal receptor expression was inversely correlated. This
finding is supported by the Southwest Oncology Group Study
and Konecney Report (Elledge et al, 1998; Ferrero-Pous et al, 2000;
Konecny et al, 2003). While previous studies have reported HER2/
neu to be a poor prognostic factor (Slamon et al, 1989; Quenel et al,
1995), neither CAV1, CAV2, nor HER2/neu appeared to be a
predictor of disease outcome in our study. This may be due to the
average follow-up period in our study being only 1141 days, such
that few disease recurrences were observed. Thus, future studies
may require longer observation periods and higher patient
numbers for analysis.
Several mechanisms could be involved in the suppression of
CAV gene expression observed in our study, including loss of
heterozygosity (LOH) (Tatarelli et al, 2000; Zenklusen et al, 2001;
Lee et al, 2002), point mutations (Hayashi et al, 2001) and
methylation (Engelman et al, 1999). As for LOH, several LOH
markers are located near the CAV1 gene locus on human
chromosome 7q31. Loss of heterozygosity is frequently encoun-
tered in this region in a variety of human neoplasias, indicating the
presence of a tumour-suppressor gene. With regard to mutation,
Hayashi et al (2001) reported CAV1 gene mutations in approxi-
mately 16% of human breast cancers, and that these mutations
may play a role in malignant progression. Although CAV1
expression is increased in prostate cancer (Yang et al, 1999),
oesophageal cancer (Kato et al, 2002) and ovarian cancer
(Davidson et al, 2001), future studies should include assessment
Table 2 Relationship between clinicopathologic characteristics and expressions of caveolin (CAV)1, caveolin (CAV)2 and HER2
CAV1 expression CAV2 expression HER2 expression
Low High P-value Low High P-value Low High P-value
Age (years) NS (0.530) NS (0.753) NS (0.116)
X55 39 42 39 41 35 45
o55 42 39 42 41 46 36
Size (cm) 0.041
a NS (0.083) NS (0.875)
X2.0 44 31 43 32 37 38
o2.0 37 50 38 49 44 43
Menopaus NS (0.512) NS (0.743) NS (0.326)
Pre 31 27 27 30 32 26
Post 50 54 53 51 49 55
n NS (0.753) NS (0.355) NS (0.529)
Positive 43 40 42 36 41 37
Negative 38 41 39 45 40 44
Ly NS (1.000) NS (0.344) NS (0.528)
Positive 37 37 40 34 35 39
Negative 44 44 41 47 46 42
V NS (0.527) NS (0.140) NS (0.833)
Positive 12 15 17 10 13 14
Negative 69 66 36 41 68 67
ER 0.021
a NS (0.053) 0.029
a
Positive 34 47 35 46 46 35
Negative 28 16 27 17 16 28
PgR NS (0.081) 0.013
a 0.019
a
Positive 35 45 33 47 46 34
Negative 27 18 29 16 16 29
aStatistical significant differences were observed between ER or PgR status and Her2 expression, between size of tumours or ER status and CAV1 expression, between PgR
status and CAV2 expression. NS¼not significant; n¼lymph node metastasis; Ly¼lymph vessel permiation; V¼vascular vessel permiation.
Table 3 Relationship among expressions of HER2, CAV1 and CAV2 in
162 cases of breast cancer
a
CAV1 high CAV1 low Total
HER2 high 42 39 81
HER2 low 39 42 81
Total 81 81 162
P-value: NS
b
CAV2 High CAV2 low Total
HER2 high 40 41 00
HER2 low 41 40 00
Total 81 81 162
P-value: NS
b
CAV1 High CAV1 Low Total
CAV2 high 59 22 00
CAV2 low 22 59 00
Total 81 81 162
P*o0.001
aA significant association was observed between CAV1 and CAV2 expressions.
bNS¼no significant difference.
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reported that the first and second exons of the CAV1 and CAV2
genes are embedded within CpG islands, such that it is possible
that caveolin gene expression is controlled, at least in part, by
methylation of these CpG regions.
Zihui et al reported that growth factor receptor stimulation
activated the phosphatidylinositol 30-kinase and b-catenin path-
ways in mammary epithelial cells. b-Catenin activates cyclin D1
and c-Myc transcription, and subsequently, c-Myc suppressing
caveolin-1 transcription (Xie et al, 2003). Furthermore, some
studies have shown that activation of HER2/neu downregulates
CAV1 expression in vitro (Couet et al, 1997; Kim et al, 2000), while
other studies have reported the negative regulation of expression
and signal transduction between CAV1 and HER2/neu (Engelman
et al, 1998; Zhang et al, 2000). However, our present study revealed
no such correlations in vivo. This may be due to a discrepancy
between experimental and clinical studies.
In summery, our results indicated that CAV1 suppression
correlated closely with that of CAV2 in breast cancer, that CAV1
level was inversely correlated with tumour size, and that CAV1 and
CAV2 levels were correlated with hormonal receptor status.
Therefore, CAV1 and CAV2 play an important role in tumour
progression in breast cancer patients.
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